A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)

Inclusion Criteria:

- Subjects must meet one of the following:

Treatment-naive (Subject has never received antiviral treatment for hepatitis C infection)
OR For Arms A, B, and C:

- Treatment Experienced (Prior null responders, Partial responders or Relapsers to
IFN/RBV)

For Arm D:

- Treatment Experienced (Prior sofosbuvir (SOF) breakthrough/non-responder or Prior SOF
relapser to SOF/pegIFN/RBV or SOF/RBV)

- Subject has plasma HCV RNA > 1000 IU/mL at Screening

- Chronic HCV genotype 4 infection with cirrhosis

Exclusion Criteria:

- Positive test result at Screening for Hepatitis B surface antigen (HBsAg) or
anti-human immunodeficiency virus antibody (HIV Ab).

- Current enrollment in another interventional clinical study, previous enrollment in
this study, or previous use of any protease inhibitor, non-nucleoside polymerase
inhibitor, or Nonstructural viral protein (NS) 5A inhibitor, either investigational
or commercially available (including previous exposure to ABT-450 or ombitasvir), or
receipt of any investigational product within 6 weeks prior to study drug
administration. Prior use of any direct-acting antiviral will not be allowed, except
for Arm D where prior experience with the nucleoside polymerase inhibitor, sofosbuvir
with pegIFN/RBV or SOF with RBV is required.

- Any current or past clinical evidence of Child-Pugh B or C classification or clinical
history of liver decompensation including ascites, variceal bleeding, or hepatic
encephalopathy.

- Confirmed presence of hepatocellular carcinoma.

- Any cause of liver disease other than chronic HCV infection.

- Abnormal laboratory tests.